Head to Head Review: Contineum Therapeutics (CTNM) and The Competition

Contineum Therapeutics (NASDAQ:CTNM) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Contineum Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, profitability and earnings.

Valuation and Earnings

This table compares Contineum Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Contineum Therapeutics	$50.00 million	-$59.98 million	-5.82
Contineum Therapeutics Competitors	$3.53 billion	$3.15 billion	552.58

Contineum Therapeutics’ rivals have higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.9% of Contineum Therapeutics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Contineum Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-25.48%	-24.28%
Contineum Therapeutics Competitors	-2,381.34%	-218.59%	-15.77%

Risk and Volatility

Contineum Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Contineum Therapeutics’ rivals have a beta of -3.77, meaning that their average share price is 477% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Contineum Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1	2	3	0	2.33
Contineum Therapeutics Competitors	7798	13891	25790	1038	2.41

Contineum Therapeutics currently has a consensus price target of $21.50, suggesting a potential upside of 108.74%. As a group, “Pharmaceuticals” companies have a potential upside of 24.92%. Given Contineum Therapeutics’ higher probable upside, research analysts clearly believe Contineum Therapeutics is more favorable than its rivals.

Summary

Contineum Therapeutics rivals beat Contineum Therapeutics on 9 of the 13 factors compared.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.